Back to results
US 2025/0205347 A1Published application
Methods for treating inflammatory conditions of the eye with an igf-1r ligand conjugated to a disease-modifying agent
AssigneeLirum Therapeutics, Inc.
InventorMatthew HOBERMAN
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for treating an inflammatory condition of the eye in a subject, comprising administering to the subject an effective amount of a conjugate that comprises an IGF-IR ligand, or portion or variant thereof, and a disease-modifying agent.
Claims61
A method for treating an inflammatory condition of the eye in a subject in need thereof, said method comprising administering to the subject a conjugate comprising an insulin-like growth factor 1 receptor (IGF-1R) ligand, or portion or variant thereof, and a disease-modifying agent.
Dependencies are inferred from the claim text.